Clinical trials: Glomerulosclerosis, Focal Segmental
Nephrotic Syndrome
Part 1 - A Clinical Trial in Patients With Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
A Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Frequently Relapsing and Steroid-Dependent Nephrotic Syndrome
- Trial name
- NCT05599815
- Testing
- ADX-629
- Where
- 11 sites in United States
- Sponsor
- Aldeyra Therapeutics, Inc.
Focal Segmental Glomerulosclerosis
Effect of Galactose on Permeblity Factor in Patients With FSGS and CKD Stage 5
This study is a proof-of-concept clinical study designed to test the hypothesis that oral administration of galactose can lower the level of a circulating factor that increases glomerular permeability to albumin in patients with…
- Trial name
- NCT00816504
- Testing
- Galactose
- Where
- United States
- Sponsor
- Northwell Health
Glomerulosclerosis, Focal Segmental, Minimal Change Disease
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease.
- Conditions
- Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
- Trial name
- NCT04235621
- Testing
- FSGS/TR-MCD, Diabetic Nephropathy (DN)
- Where
- 18 sites in United States
- Volunteers
- 20 people
- Sponsor
- Goldfinch Bio, Inc.
Primary Focal Segmental Glomerulosclerosis
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS
The purpose of this study is to determine whether Rituximab therapy is safe and effective in treating patients with the kidney condition, focal segmental glomerulosclerosis (FSGS), that is no longer responsive to traditional…
- Trial name
- NCT01573533
- Testing
- Rituximab
- Where
- 4 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Mayo Clinic
Kidney Diseases
Global Kidney Patient Trials Network
This is a prospective international multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease
- Trial name
- GKPTN (NCT04389827)
- Where
- Australia
- Volunteers
- 5,999 people
- Sponsor
- The George Institute
Focal Segmental Glomerulosclerosis
Safety and Pharmacokinetics of FG-3019 in Adolescents and Adults With Focal Segmental Glomerulosclerosis (FSGS)
The purpose of this study is to evaluate the safety and tolerability of FG-3019 administered over 8 weeks to adolescent and adult subjects with steroid-resistant focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT00782561
- Testing
- FG-3019
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Kyntra Bio
Nephrotic Syndrome in Children, Minimal Change Disease
A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)
Children with steroid resistant nephrotic syndrome (SRNS) are exposed to prolonged courses of immunosuppressant medications. Given the adverse side effect profiles and variable efficacy of these medications, there is an urgent…
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- kidNEY-VNS (NCT05583942)
- Testing
- trascutaneous auricular vagus nerve stimulation
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Northwell Health
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
Glomerulosclerosis, Focal
Total Lymphoid Irradiation (TLI) to Prevent Focal Segmental Glomerulosclerosis (FSGS)Recurrence in the Renal Graft
The purpose was study the immunosuppression using total lymphoid irradiation plus Csa, MMF and prednisone pretransplant to prevent focal segmental glomerulosclerosis recurrence in the renal graft
- Trial name
- NCT00353535
- Testing
- Total Lymphoid irradiation
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- University of Sao Paulo
FSGS, Focal Segmental Glomerulosclerosis
A Study of CCX140-B in Subjects With FSGS
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects with FSGS to be conducted in the North America, Europe and Australia
- Conditions
- FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
- Trial name
- NCT03536754
- Testing
- CCX140-B
- Where
- 37 sites in United States, Australia and 6 more
- Volunteers
- 46 people
- Sponsor
- Amgen
Focal Segmental Glomerulosclerosis
LDL-Apheresis for FSGS CardioRenal Outcomes
Focal segmental glomerulosclerosis (FSGS) is the most common cause of end-stage renal disease (ESRD) in adolescents. The refractory nature of FSGS and a more than 30% recurrence rate after kidney transplantation renders treatment…
- Trial name
- NCT04088799
- Testing
- No intervention
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Glomerulonephritis, Focal Segmental Glomerulosclerosis
Predictors of Disease Progression in Primary Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS) is one of the most common primary glomerular diseases leading to end stage renal disease.
- Trial name
- NCT03126201
- Where
- Turkey (Türkiye)
- Volunteers
- 86 people
- Sponsor
- Istanbul University
Minimal Change Disease (MCD), Membranous Nephropathy
Nephrotic Syndrome Study Network
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage…
- Conditions
- Minimal Change Disease (MCD), Membranous Nephropathy, Glomerulosclerosis, Focal Segmental
- Trial name
- NEPTUNE (NCT01209000)
- Testing
- Kidney Biopsy
- Where
- 44 sites in United States, Canada
- Volunteers
- 1,200 people
- Sponsor
- University of Michigan
Fluid Overload, Glomerulosclerosis, Focal Segmental
Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.
Researchers from the University of Michigan and Northwestern University are studying people's experiences with swelling caused by Nephrotic Syndrome.
- Conditions
- Fluid Overload, Glomerulosclerosis, Focal Segmental, Edema, Membranous Nephropathy
- Trial name
- Prepare-NS (NCT05505500)
- Testing
- Interview
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- University of Michigan
Childhood Idiopathic Nephrotic Syndrome
Efficacy of Rituximab For the Treatment of Calcineurin Inhibitors Dependent Nephrotic Syndrome During Childhood
Background Idiopathic nephrotic syndrome is a rare disease beginning during childhood and treated with immunosuppressants (i.e. steroids, mycophenolate mofetil, cyclophosphamide, cyclosporine).
- Trial name
- NEPHRUTIX (NCT01268033)
- Testing
- Rituximab
- Where
- 24 sites in Belgium, France
- Volunteers
- 26 people
- Sponsor
- University Hospital, Limoges
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and…
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Trial name
- RESOLVE (NCT05650619)
- Testing
- Biospecimen collection, Data collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Michigan
Focal Segmental Glomerulosclerosis, HIV-Associated Focal Segmental Glomerulosclerosis
Genetic Markers for Focal Segmental Glomerulosclerosis
Glomerulonephritis is a disease which affect the kidneys. Occasionally these diseases can progress to a loss of kidney function in some patients.
- Trial name
- NCT00001393
- Where
- United States
- Volunteers
- 616 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Alport Syndrome, Focal Segmental Glomerulosclerosis
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary…
- Trial name
- NCT05267262
- Testing
- R3R01
- Where
- 22 sites in United States, Belgium and 4 more
- Volunteers
- 43 people
- Sponsor
- River 3 Renal Corp.
ANCA Associated Vasculitis, Extramembranous Glomerulopathy
Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis
The project is to explore in humans the hypothesis of the link between the alteration of tubulo-interstitial metabolism and the rate of deterioration of renal function by comparing various nephropathies.
- Conditions
- ANCA Associated Vasculitis, Extramembranous Glomerulopathy, Nephrotic Syndrome, Minimal Change, Interstitial Nephritis
- Trial name
- PROTECT-Fi (NCT07010250)
- Where
- France
- Volunteers
- 146 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Focal Glomerulosclerosis
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)
The current management of primary FSGS is predicated on the assumption that the disease is caused by an immune-mediated disturbance in glomerular barrier function.
- Trial name
- NCT00193648
- Testing
- Rosiglitazone (Avandia), Adalimumab (Humira)
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Northwell Health